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During the first two years’ follow-up, hospital admissions were significantly lower 
in controls (p< 0.0001 vs PAP for both years); number of admissions was 5,323 in 
the control group and 6,931 in the PAP group. Conversely, in year 3 of follow-up, the 
number of inpatient treatments was significantly lower in the PAP vs control group 
(1,525 vs 2,000; p< 0.0001). Total cost of illness was higher in the PAP group compared 
with controls (year 1: € 6,704 vs € 5,015 [p< 0.0001]; year 2: € 5,272 vs € 4,901 [p< 0.001]; 
year 3: € 5,091 vs € 4,830 [p< 0.001]). Recipients of PAP therapy had a significantly 
lower 3-year mortality rate compared with controls (4.5% vs 7.2%; p< 0.0001; rela-
tive risk reduction 37.5%). ConClusions: SA patients with PAP therapy showed a 
significantly reduced mortality and morbidity. Also, the data showed that treatment 
may begin to have beneficial effects on the hospitalisation rate after 2 years of treat-
ment. Costs of PAP remained higher than control over the first 3 years of therapy, 
although the difference between treatment groups reduced over time. A follow-up 
period of ≥ 5 years may be required to show beneficial economic outcomes in SA 
patients receiving PAP therapy.
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objeCtives: To characterize psychiatric health care utilization and its related costs in 
a cohort of newly diagnosed ASD individuals. Methods: A cohort was built using the 
provincial public health care insurance program (RAMQ) databases. Newly diagnosed 
subjects with ASD were selected (≥ 2 diagnoses (separate dates) with ICD-9 codes: 
299.X, excluding 299.2) between January 1998 and December 2010. Cohort entry was 
the date of first diagnosis confirmed by the absence of ASD diagnosis in previous 5 
years. Participants aged ≥ 26 years or those not covered by the RAMQ drug plan in the 
year preceding cohort entry were excluded. Demographic and clinical patient charac-
teristics were done at cohort entry. Health care utilisation associated with a psychi-
atric diagnosis (physician and emergency room visits, hospitalisations), psychoactive 
drug use (anticonvulsants, antipsychotics, antidepressants, anxiolytics, ADHD drugs) 
and total cumulative costs were assessed across 5 years of follow-up. Results: A 
number of 1227 patients among the total cohort had 5 years of follow-up (male: 80.3%; 
median age: 7 years). In the 1-year following diagnosis, the mean number of visits to 
general practitioners was 1.6 whereas psychiatry related visits to specialists were 7.2 
which decreased over time. Psychoactive drug utilisation was initially present in 49.3% 
of participants, and increased to 53.2% at 5 years. The psychiatric hospitalization rate 
was 10.4% in the 1-year of follow-up with the highest rates seen in adolescents (20%) 
and young adults (24%). Cumulative costs of psychiatric health services and psycho-
active drugs at 1-year of follow-up were $547,568CAD and $600,433CAD, respectively. 
Those costs were at $216,827CAD and $934,381CAD at 5-years. ConClusions: While 
cost related to psychiatric health care services decreased by more than half in the 5 
years of follow-up, drug costs rose by 56%. Access to long term care and monitoring 
among the ASD population is discussed.
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objeCtives: Endometriosis takes the third place in the structure of the gyneco-
logical pathology after inflammatory diseases of the female genital organs and 
uterine fibroids. Endometriosis is most commonly diagnosed in women between 
30 and 40 years of age - reproductive and functional age. The aim of the study was 
to calculate the average cost of hormonal therapy of endometriosis in Ukraine for 
a minimum period of 6 months, considering that the main aim of this therapy 
is the elimination of two major problems such as endometriosis-associated pain 
(dysmenorrhea, dyspareunia, chronic pelvic pain, ovulation-related pain, dysche-
zia) and infertility. Methods: We analyzed the cost of treatment hormones per 
patient for course. We used the real data from medical records of patients who were 
treated in a regional perinatal center in Lviv. We have analyzed almost 150 stories 
diseases for 2012-2013. We used the prices from Ukrainian database of Morion com-
pany (Kiev) on 01.01.2014 (1 USD = 8,24 UAH). Results: In Ukraine for treatment 
of endometriosis often use these three alternative treatment hormonal schemes. 
We calculated the costs for course per patient in 6 months duration. The treatment 
costs are Dydrogesterone (tab. 10 mg №20) - 345 USD (2843 UAH); Dienogest (tab. 2 mg 
№28) - 550 USD (4530 UAH); Triptorelin (powder for susp. for injection 3,75 mg) - 1347 
USD (11097 UAH). ConClusions: The alternative hormonal treatment schemes of 
endometriosis are differences 4 times per 1 patient for 6 months duration. Almost 
patient fully pay costs out of pocket, through this treatment costs are quite high for 
Ukrainian women. These results support the need to provide some state funding 
for the treatment of endometriosis and introduction the reimbursement system for 
hormonal medicine in Ukraine.
PIH27
tHe cost-effectIveness of PosItron emIssIon tomograPHy (Pet): a 
systematIc revIew across mUltIPle IndIcatIons
Cangelosi M.J, Saunders T., Neumann P.J., Chambers J.D.
Tufts Medical Center, Boston, MA, USA
objeCtives: To review the cost-effectiveness literature evaluating positron emis-
sion tomography (PET) imaging. Methods: We systematically searched the PubMed 
database and the Tufts Medical Center Cost-Effectiveness Analysis Registry to 
identify studies evaluating the economics of PET imaging. We categorized each 
study with respect to indication, i.e., cardiology, neurology, oncology, and other. 
We extracted data pertaining to: the date of publication; the region in which the 
significantly (p< 0.01) higher rates of outpatient visits, ambulatory surgical center 
visits, physical therapy visits, anti-depressant use and ED prescription use com-
pared to controls. Compared with their controls, Medicare PD patients had on 
average significantly higher risk-adjusted all-cause outpatient costs ($5,322 vs. 
$3,162) and annual all-inclusive health care costs ($10,675 vs. $7,926); risk-adjusted 
annual total all-cause costs for the commercial cohort were $10,463 vs. $5,918 (all 
p< 0.0001). ConClusions: PD patients had higher comorbidity rates, utilization, 
and annual total costs compared with matched controls.
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objeCtives: Hospital costs for newborns are indirectly associated with gestational 
age (GA) at birth. The higher costs of prematurity are primarily a function of the 
presence of clusters of comorbidities. The objective of this study was to explore 
the incremental costs associated with having neonatal comorbidities of prematu-
rity, and whether stable cost estimates can be derived for use in economic evalua-
tions. Methods: Our analyses included 4292 hospital records from infants (23-37 
wks GA) born to mothers with uncomplicated singleton pregnancies in spontane-
ous preterm labor at the Medical University of South Carolina from 2001-2010 . 
Thirteen comorbidities associated with prematurity were identified: respiratory 
distress syndrome (RDS), bronchopulmonary dysplasia (BPD), sepsis, meningitis, 
necrotizing enterocolitis (NEC), intraventricular hemorrhage I & II and III & IV (IVH 
I/II & IVH III/IV), periventricular leukomalacia (PVL), anemia, apnea, retinopathy 
of prematurity requiring surgery (ROP), convulsions, and brain injury (PVL/CPV). 
To estimate incremental cost of each, adjusted for other comorbidities and GA, 
we transformed the data and implemented a partial least squares model, with 10 
fold-cross validation of the full model. Results: Transformation of the data and 
implementation of the partial least squares model eliminated collinearity issues 
in the data leading to stable incremental cost estimates, Q2= 0.69. The model was 
found to be stable under bootstrapping. Cost outliers were retained in the model as 
the incremental costs estimates were stable and the model had good predictability 
when they were retained. Incremental costs ranged from $23,121 (ROP) to $4,529 
(convulsions). ConClusions: In addition to GA at birth, these 13 comorbidities of 
prematurity impact total hospital costs of premature infants. This study provides 
reliable estimates of the incremental cost associated with comorbidities of prema-
turity, controlling for GA at birth, to be used in future economic analyses of the cost 
associated with premature birth due to spontaneous preterm labor.
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objeCtives: To estimate the economic burden of unintended pregnancy in the 
perspective of public payer and the impact of UP on related public health meas-
ures in Brazil. Methods: A decision-analysis cost model was constructed based 
on pregnancy rates, probabilities and costs of pregnancy and neonatal outcomes 
(miscarriage, induced abortion, and live birth) in Brazil. The model took account of 
both maternal and child outcomes, and accounted for health care costs related with 
preterm birth, neonatal admission, cerebral palsy, neonatal and maternal mortality. 
All costs are reported as Real$ (Brazilian currency). Results: In Brazil there were 1.8 
million unintended pregnancies in 2010. Those unintended pregnancies resulted in 
159,151 miscarriages, 48,769 induced abortions, and 1.58 million live births. It was 
estimated there were 312 maternal deaths. The number of infant deaths within the 
12-months following birth was estimated at 32,864. The total health care costs to 
public payer attributed to unintended pregnancies are estimated to be R$4.1 billion 
in one year of which R$4.07 billion (99.2%) attributed to births and resulting com-
plications and R$32 million (0.8%) was attributed to miscarriage. The average cost 
per UP was R$2,293. ConClusions: Unintended pregnancies impose substantial 
burden on the Brazilian society in term of health care costs, infant and maternal 
morbidity and mortality. Reduction in UPs will not only generate substantial cost-
savings, but also improve public health profile of the country. Public policymakers 
should allocate budget on cost-effective pregnancy prevention interventions to 
address this issue.
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objeCtives: Sleep apnea (SA) is relatively common, occurring in about 2–4% of the 
general population. This study investigated the effects of PAP therapy on morbidity 
(including comorbid disease), all-cause mortality, and costs in patients with SA. 
A statutory health insurance (SHI) perspective was taken. Methods: A total of 
approx. 4 million individuals covered by the SHI database were analysed (ca. 5% of 
the German SHI population). PAP therapy was initiated in 4068 patients with SA. 
Propensity score was used to define a control group of 4068 SA patients matched 
for age, sex, risk factors/etiology, region and medication who received usual care 
(no PAP). Patients were followed after therapy initiation over three years. Results: 
